Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 231

The DOI matches its Crossref record.

ErbB-3 Predicts Survival in Ovarian Cancer

Tanner, Berno, Hasenclever, Dirk, Stern, Katja, Schormann, Wiebke, Bezler, Martin, Hermes, Matthias, Brulport, Marc, Bauer, Alexander, Schiffer, Ilka B., Gebhard, Susanne, Schmidt, Markus, Steiner, Eric, Sehouli, Jalid, Edelmann, Jeanett, Läuter, Jürgen, Lessig, Rüdiger, Krishnamurthi, K., Ullrich, Axel, Hengstler, Jan Georg · 2006 · Journal of Clinical Oncology

Abstract

Background: HER3 (erbB-3) is a member of the epidermal growth factor receptor (EGFR) family. After dimerization with other members of the EGFR family several signal transduction cascades can be activated, including phosphoinosite 3′-kinase (PI3-K)/Akt and extracellular signal-regulated kinase (ERK1/2). Here, we studied a possible association between HER3 expression and prognosis in patients with ovarian cancer. Methods: Tumor tissue of 116 consecutive patients diagnosed with primary epithelial ovarian cancer between 1986 and 1995 was analyzed immunohistochemically for HER3 expression. A possible influence of HER3 expression on survival was studied by multivariate Cox regression adjusting for established clinical prognostic factors. Results: A positive HER3 expression was observed in 53.4% of the patients. HER3 expression was associated with decreased survival in proportional hazard modeling, including the International Federation of Gynecology and Obstetrics (FIGO) stage, histologic grade and type, residual disease, and age. After likelihood ratio forward as well as backward selection, only HER3 expression (hazard ratio, 1.71; 95% CI, 1.10 to 2.67; P = .018), FIGO stage (hazard ratio, 4.78; 95% CI, 1.89 to 12.08; P = .001), residual tumor (hazard ratio, 2.69; 95% CI, 1.40 to 5.17; P = .003), and age (hazard ratio, 2.06; 95% CI, 1.17 to 3.65; P = .013) were found to be significant. Kaplan-Meier plots demonstrated a clear influence of HER3 expression on survival time. Median survival time was 3.31 years (95% CI, 1.93 to 4.68) for patients with low HER3 expression, compared with only 1.80 years (95% CI, 0.83 to 2.78) for patients with HER3 overexpression (log-rank test P = .0034). Conclusion: HER3 may represent a new prognostic factor in primary epithelial ovarian cancer. Pending validation, exploration of therapeutic strategies to block HER3 could be warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2005.04.8397

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 231

Metadata

Authors
Tanner, B., Hasenclever, D., Stern, K., Schormann, W., Bezler, M., Hermes, M., Brulport, M., Bauer, A., Schiffer, I. B., Gebhard, S., Schmidt, M., Steiner, E., Sehouli, J., Edelmann, J., Läuter, J., Lessig, R., Krishnamurthi, K., Ullrich, A., & Hengstler, J. G.
Venue
Journal of Clinical Oncology
Published
2006-09-10
Volume
24
Issue
26
Pages
4317-4323
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2036253797
Cited by
231
References
0
FWCI
11.86
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ErbB-3 Predicts Survival in Ovarian Cancer. https://app.cochat.ai/papers/10.1200/jco.2005.04.8397
The paper
Tanner, B., Hasenclever, D., Stern, K., Schormann, W., Bezler, M., Hermes, M., Brulport, M., Bauer, A., Schiffer, I. B., Gebhard, S., Schmidt, M., Steiner, E., Sehouli, J., Edelmann, J., Läuter, J., Lessig, R., Krishnamurthi, K., Ullrich, A., & Hengstler, J. G. (2006). ErbB-3 Predicts Survival in Ovarian Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.04.8397

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.